Wearable ECG Garment for Spotting Atrial Fibrillation and Assessing Stroke Risk
Looks at a wearable ECG garment for finding atrial fibrillation in high stroke risk patients.
Plain-language title generated from the registry record
Registry title: Wearable ECG for AF Screening and Stroke Risk Assessment
Key facts
- Where
- Beijing, ChinaSee the 2 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 40 and older who have a high risk of stroke. They wear an ECG garment for 24 hours to check for atrial fibrillation.
- Age
- 40 years and older
- Sex
- Men and women can join.
- Disease stage
- High risk of stroke, as found by the "8+2" risk score in stroke screening.
Main reasons for not taking part
- Severe illness that limits wearing the device (for example advanced cancer, severe infection, Class IV heart failure) or hospice care
- Cannot use the device or understand the study because of cognitive impairment, mental illness, or language barriers
- May have severe discomfort or an allergic reaction from wearing the device
- Already uses an implanted heart monitoring device
Read by machine on 9 November 2026.
Where in China
- Beijing Tsinghua Changgung HospitalBeijing, ChinaNo longer taking part
- Pinggu District HospitalBeijing, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Beijing Tsinghua Chang Gung Hospital
- Trial code
- NCT06907264
- Record updated
- 2 April 2025
- Original description
This study aims to evaluate the application of wearable ECG garments in atrial fibrillation (AF) screening and stroke risk assessment. Using a prospective, multicenter, observational design, the study will recruit high-risk stroke patients aged 40 and above to undergo 24-hour continuous ECG monitoring with wearable ECG garments. The study will assess the detection rate of AF and explore the correlation between heart rate variability (HRV) parameters and stroke risk. Additionally, the study will analyze the association between P-wave indices and AF, and evaluate the acceptability of the device among patients and healthcare providers. The primary goal is to validate the accuracy of wearable ECG garments in AF detection and explore their predictive value for stroke risk in high-risk populations.Read full original descriptionShow less
Application of Wearable ECG Garments in Atrial Fibrillation Screening and Stroke Risk Assessment
This study aims to evaluate the application of wearable ECG garments in atrial fibrillation (AF) screening and stroke risk assessment. Using a prospective, multicenter, observational design, the study will recruit high-risk stroke patients aged 40 and above to undergo 24-hour continuous ECG monitoring with wearable ECG garments. The study will assess the detection rate of AF and explore the correlation between heart rate variability (HRV) parameters and stroke risk. Additionally, the study will analyze the association between P-wave indices and AF, and evaluate the acceptability of the device among patients and healthcare providers. The primary goal is to validate the accuracy of wearable ECG garments in AF detection and explore their predictive value for stroke risk in high-risk populations.
Inclusion: Age ≥ 40 years; High-risk stroke population identified by the "8+2" risk score in stroke screening; Ability to operate the device independently or with assistance from family members; Willingness to participate in the study and provide signed informed consent.
Exclusion: Patients with severe diseases that limit device wear (e.g., advanced malignant tumors, severe infections, Class IV heart failure) or those receiving hospice care; Patients unable to operate the device or understand the study procedures due to cognitive impairment, mental illness, or language communication barriers; Patients who may experience severe discomfort or allergic reactions from wearing the device; Patients already using implanted cardiac monitoring devices.